Insiders · AKRO

Jonathan Young

Chief Operating Officer at Akero Therapeutics, Inc. (AKRO)

Jonathan Young has filed 54 insider reports with the SEC since February 2021, as chief Operating Officer at Akero Therapeutics, Inc. (AKRO). Jonathan Young made no open-market purchases or sales in the last 12 months. The latest filing, on December 9, 2025, reports sale back to the company at Akero Therapeutics, Inc. (AKRO).

Filings
54
Companies
1
Bought on market
None
Sold on market
$13.1M

Companies where Jonathan Young is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Akero Therapeutics, Inc. logo
AKRO
Akero Therapeutics, Inc.
Chief Operating Officer0$13.1MDec 9, 2025

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Jonathan Young with

Other insiders at the same companies

Questions about Jonathan Young

What is Jonathan Young's role at Akero Therapeutics, Inc.?
Jonathan Young reports to the SEC as chief Operating Officer at Akero Therapeutics, Inc. (AKRO), according to the latest filing on December 9, 2025.
Has Jonathan Young bought or sold stock recently?
The most recent open-market sale was on October 1, 2025: sold 12,500 shares of Akero Therapeutics, Inc. (AKRO) for $597K at an average of $47.76.
How do I get alerts when Jonathan Young files?
Follow Jonathan Young on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Jonathan Young (SEC CIK 0001779805). Totals count each trade once, skipping amendments whose original is on file, from Feb 2, 2021 on. View on SEC EDGAR · Get this as JSON